Comparative genomics of non-pseudomonal bacterial species colonising paediatric cystic fibrosis patients

PeerJ

Volumn 2015, Issue 9, 2015, Pages

  Ormerod, Kate L ^a   George, Narelle M ^b   Fraser, James A ^a   Wainwright, Claire ^a,c,d   Hugenholtz, Philip ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QUEENSLAND HEALTH   (Australia)

^c LADY CILENTO CHILDREN S HOSPITAL   (Australia)

^d Queensland Children's Medical Research Institute   (Australia)

Author keywords

Antibiotic resistance; Comparative genomics; Cystic fibrosis; Host adaptation; Lateral gene transfer; Microevolution; Serial isolates

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE;

ACHROMOBACTER XYLOSOXIDANS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC RESISTANCE GENE; ANTIBIOTIC SENSITIVITY; ARTICLE; CHILD; CHILDHOOD DISEASE; CYSTIC FIBROSIS; DNA EXTRACTION; ENTEROBACTER CLOACAE; GENE; GENE SEQUENCE; GENOME ANALYSIS; GENOMICS; HUMAN; LUNG LAVAGE; MICROBIAL COLONIZATION; PRESCHOOL CHILD; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA;

EID: 84944894240     PISSN: None     EISSN: 21678359     Source Type: Journal    
DOI: 10.7717/peerj.1223     Document Type: Article

References (98)

1. Amoureux L, Bador J, Fardeheb S, Mabille C, Couchot C, Massip C, Salignon A-L, Berlie G, Varin V, Neuwirth C. 2013a. Detection of Achromobacter xylosoxidans in hospital, domestic, and outdoor environmental samples and comparison with human clinical isolates. Applied and Environmental Microbiology 79(23):7142-7149 DOI 10.1128/AEM.02293-13.
2. Amoureux L, Bador J, Siebor E, Taillefumier N, Fanton A, Neuwirth C. 2013b. Epidemiology and resistance of Achromobacter xylosoxidans from cystic fibrosis patients in Dijon, Burgundy: first French data. Journal of Cystic Fibrosis 12(2):170-176 DOI 10.1016/j.jcf.2012.08.005.
3. Avison MB, Higgins CS, Von Heldreich CJ, Bennett PM, Walsh TR. 2001. Plasmid location and molecular heterogeneity of the L1 and L2 β-lactamase genes of Stenotrophomonas maltophilia. Antimicrobial Agents and Chemotherapy 45(2):413-419 DOI 10.1128/AAC.45.2.413-419.2001.
4. Aziz RK, Bartels D, Best AA, DeJongh M, Disz T, Edwards RA, Formsma K, Gerdes S, Glass EM, Kubal M, Meyer F, Olsen GJ, Olson R, Osterman AL, Overbeek RA, McNeil LK, Paarmann D, Paczian T, Parrello B, Pusch GD, Reich C, Stevens R, Vassieva O, Vonstein V, Wilke A, Zagnitko O. 2008. The RAST Server: rapid annotations using subsystems technology. BMC Genomics 9:75 DOI 10.1186/1471-2164-9-75.
5. Bador J, Amoureux L, Blanc E, Neuwirth C. 2013. Innate aminoglycoside resistance of Achromobacter xylosoxidans is due to AxyXY-OprZ, an RND-type multidrug efflux pump. Antimicrobial Agents and Chemotherapy 57(1):603-605 DOI 10.1128/AAC.01243-12.
6. Bador J, Amoureux L, Duez J-M, Drabowicz A, Siebor E, Llanes C, Neuwirth C. 2011. First description of an RND-type multidrug efflux pump in Achromobacter xylosoxidans, AxyABM. Antimicrobial Agents and Chemotherapy 55(10):4912-4914 DOI 10.1128/AAC.00341-11.
7. Bittar F, Richet H, Dubus J-C, Reynaud-Gaubert M, Stremler N, Sarles J, Raoult D, Rolain J-M. 2008. Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients. PLoS ONE 3(8):e2908 DOI 10.1371/journal.pone.0002908.
8. Bokarewa MI, Jin T, Tarkowski A. 2006. Staphylococcus aureus: Staphylokinase. The International Journal of Biochemistry & Cell Biology 38(4):504-509 DOI 10.1016/j.biocel.2005.07.005.
9. Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30(15):2114-2120 DOI 10.1093/bioinformatics/btu170.
10. Boucher RC. 2007. Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annual Review of Medicine 58(1):157-170 DOI 10.1146/annurev.med.58.071905.105316.
11. Branger C, Gardye C, Lambert-Zechovsky N. 1996. Persistence of Staphylococcus aureus strains among cystic fibrosis patients over extended periods of time. Journal of Medical Microbiology 45(4):294-301 DOI 10.1099/00222615-45-4-294.
12. Brogden KA, Guthmiller JM, Taylor CE. 2005. Human polymicrobial infections. The Lancet 365(9455):253-255 DOI 10.1016/S0140-6736(05)70155-0.
13. Brooke JS. 2012. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clinical Microbiology Reviews 25(1):2-41 DOI 10.1128/CMR.00019-11.
14. Cardines R, Giufrè M, Pompilio A, Fiscarelli E, Ricciotti G, Bonaventura GD, Cerquetti M. 2012. Haemophilus influenzae in children with cystic fibrosis: antimicrobial susceptibility, molecular epidemiology, distribution of adhesins and biofilm formation. International Journal of Medical Microbiology 302(1):45-52 DOI 10.1016/j.ijmm.2011.08.003.
15. Chen K, Wallis JW, McLellan MD, Larson DE, Kalicki JM, Pohl CS, McGrath SD, Wendl MC, Zhang Q, Locke DP, Shi X, Fulton RS, Ley TJ, Wilson RK, Ding L, Mardis ER. 2009. BreakDancer: an algorithm for high-resolution mapping of genomic structural variation. Nature Methods 6(9):677-681 DOI 10.1038/nmeth.1363.
16. Chen L, Xiong Z, Sun L, Yang J, Jin Q. 2012. VFDB 2012 update: toward the genetic diversity and molecular evolution of bacterial virulence factors. Nucleic Acids Research 40(D1):D641-D645 DOI 10.1093/nar/gkr989.
17. Cheung AL, Bayer AS, Zhang G, Gresham H, Xiong YQ. 2004. Regulation of virulence determinants in vitro and in vivo in Staphylococcus aureus. FEMS Immunology and Medical Microbiology 40(1):1-9 DOI 10.1016/S0928-8244(03)00309-2.
18. Ciofu O, Beveridge TJ, Kadurugamuwa J, Walther-Rasmussen J, Høiby N. 2000. Chromosomal β-lactamase is packaged into membrane vesicles and secreted from Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy 45(1):9-13 DOI 10.1093/jac/45.1.9.
19. Conway SP, Brownlee KG, Denton M, Peckham DG. 2003. Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis. American Journal of Respiratory Medicine: Drugs, Devices, and Other Interventions 2(4):321-332 DOI 10.1007/BF03256660.
20. Cox MJ, Allgaier M, Taylor B, Baek MS, Huang YJ, Daly RA, Karaoz U, Andersen GL, Brown R, Fujimura KE, Wu B, Tran D, Koff J, Kleinhenz ME, Nielson D, Brodie EL, Lynch SV. 2010. Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients. PLoS ONE 5(6):e11044 DOI 10.1371/journal.pone.0011044.
21. Crossman L, Gould V, Dow JM, Vernikos G, Okazaki A, Sebaihia M, Saunders D, Arrowsmith C, Carver T, Peters N, AdlemE, Kerhornou A, Lord A, Murphy L, Seeger K, Squares R, Rutter S, Quail M, Rajandream M-A, Harris D, Churcher C, Bentley S, Parkhill J, Thomson N, Avison M. 2008. The complete genome, comparative and functional analysis of Stenotrophomonas maltophilia reveals an organism heavily shielded by drug resistance determinants. Genome Biology 9(4):Article R74 DOI 10.1186/gb-2008-9-4-r74.
22. Dalbøge CS, Hansen CR, Pressler T, Høiby N, Johansen HK. 2011. Chronic pulmonary infection with Stenotrophomonas maltophilia and lung function in patients with cystic fibrosis. Journal of Cystic Fibrosis 10(5):318-325 DOI 10.1016/j.jcf.2011.03.006.
23. Darling AE, Mau B, Perna NT. 2010. progressiveMauve: multiple genome alignment with gene gain, loss and rearrangement. PLoS ONE 5(6):e11147 DOI 10.1371/journal.pone.0011147.
24. De Haas CJC, Veldkamp KE, Peschel A, Weerkamp F, VanWamel WJB, Heezius E, Poppelier M, Van Kessel KPM, Van Strijp JAG. 2004. Chemotaxis inhibitory protein of Staphylococcus aureus, a bacterial antiinflammatory agent. Journal of Experimental Medicine 199(5):687-695 DOI 10.1084/jem.20031636.
25. DePristo M, Banks E, Poplin R, Garimella K, Maguire J, Hartl C, Philippakis A, Del Angel G, Rivas MA, Hanna M, McKenna A, Fennell T, Kernytsky A, Sivachenko A, Cibulskis K, Gabriel S, Altshuler D, Daly M. 2011. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nature Genetics 43(5):491-498 DOI 10.1038/ng.806.
26. Dhillon BK, Chiu TA, Laird MR, Langille MGI, Brinkman FSL. 2013. IslandViewer update: improved genomic island discovery and visualization. Nucleic Acids Research 41(W1):W129-W132 DOI 10.1093/nar/gkt394.
27. Dickson RP, Erb-Downward JR, Huffnagle GB. 2013. The role of the bacterial microbiome in lung disease. Expert Review of Respiratory Medicine 7(3):245-257 DOI 10.1586/ers.13.24.
28. Doering G, Flume P, Heijerman H, Elborn JS, Angyalosi G, Assael B, Bell S, Bilton D, De Boeck K, Bush A, Campbell III PW, Cattaneo A, Dembowsky K, Drevinek P, Dubois C, Eichler I, Elborn JS, Flume PA, Foweraker JE, Gallagher C, Gartner S, Geller DE, Goldman M, Goss CH, Gupta R, Heijerman HG, Henig N, Higgins M, Hjelte L, Hoiby N, Jongejan R, Knoch M, Konstan MW, Muhlebach MS, Nieuwenhuizen PW, Parkins MD, Pressler T, Quittner AL, Ratjen F, Ramsey BW, Smyth A, Thieroff-Ekerdt R, Tullis E, Van der Ent CK, Vazquez C, Wainwright CE, Consensus Study Group. 2012. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. Journal of Cystic Fibrosis 11(6):461-479 DOI 10.1016/j.jcf.2012.10.004.
29. Doern GV, Brecher SM. 2011. The clinical predictive value (or lack thereof) of the results of in vitro antimicrobial susceptibility tests. Journal of Clinical Microbiology 49(9 Supplement):S11-S14 DOI 10.1128/JCM.00580-11.
30. Ecevit IZ, McCrea KW, Pettigrew MM, Sen A, Marrs CF, Gilsdorf JR. 2004. Prevalence of the hifBC, hmw1A, hmw2A, hmwC, and hia genes in Haemophilus influenzae isolates. Journal of Clinical Microbiology 42(7):3065-3072 DOI 10.1128/JCM.42.7.3065-3072.2004.
31. Emerson J, McNamara S, Buccat AM, Worrell K, Burns JL. 2010. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008. Pediatric Pulmonology 45(4):363-370 DOI 10.1002/ppul.21198.
32. Enright MC, Day NPJ, Davies CE, Peacock SJ, Spratt BG. 2000. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. Journal of Clinical Microbiology 38(3):1008-1015.
33. Erwin AL, Sandstedt SA, Bonthuis PJ, Geelhood JL, Nelson KL, Unrath WCT, Diggle MA, Theodore MJ, Pleatman CR, Mothershed EA, Sacchi CT, Mayer LW, Gilsdorf JR, Smith AL. 2008. Analysis of genetic relatedness of Haemophilus influenzae isolates by multilocus sequence typing. Journal of Bacteriology 190(4):1473-1483 DOI 10.1128/JB.01207-07.
34. Fux CA, Costerton JW, Stewart PS, Stoodley P. 2005. Survival strategies of infectious biofilms. Trends in Microbiology 13(1):34-40 DOI 10.1016/j.tim.2004.11.010.
35. Galardini M, Biondi EG, Bazzicalupo M, Mengoni A. 2011. CONTIGuator: a bacterial genomes finishing tool for structural insights on draft genomes. Source Code for Biology and Medicine 6:11-11 DOI 10.1186/1751-0473-6-11.
36. Glupczynski Y, Hansen W, Freney J, Yourassowsky E. 1988. In vitro susceptibility of Alcaligenes denitrificans subsp. xylosoxidans to 24 antimicrobial agents. Antimicrobial Agents and Chemotherapy 32(2):276-278 DOI 10.1128/AAC.32.2.276.
37. Gordon LA. 1998. Staphylococcus aureus: a well-armed pathogen. Clinical Infectious Diseases 26(5):1179-1181 DOI 10.1086/520289.
38. Goris J, Konstantinidis KT, Klappenbach JA, Coenye T, Vandamme P, Tiedje JM. 2007. DNA-DNA hybridization values and their relationship to whole-genome sequence similarities. International Journal of Systematic and Evolutionary Microbiology 57:81-91 DOI 10.1099/ijs.0.64483-0.
39. Goss CH, Mayer-Hamblett N, Aitken ML, Rubenfeld GD, Ramsey BW. 2004. Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis. Thorax 59(11):955-959 DOI 10.1136/thx.2003.017707.
40. Hampton TH, Green DM, Cutting GR, Morrison HG, Sogin ML, Gifford AH, Stanton BA, O'Toole GA. 2014. The microbiome in pediatric cystic fibrosis patients: the role of shared environment suggests a window of intervention. Microbiome 2:Article 14 DOI 10.1186/2049-2618-2-14.
41. Hansen CR. 2012. Stenotrophomonas maltophilia: to be or not to be a cystic fibrosis pathogen. Current Opinion in Pulmonary Medicine 18(6):628-631 DOI 10.1097/MCP.0b013e328358d4f8.
42. Hansen CR, Pressler T, Nielsen KG, Jensen PØ, Bjarnsholt T, Høiby N. 2010. Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients. Journal of Cystic Fibrosis 9(1):51-58 DOI 10.1016/j.jcf.2009.10.005.
43. Hanssen AM, Sollid JUE. 2006. SCCmec in staphylococci: genes on the move. FEMS Immunology and Medical Microbiology 46(1):8-20 DOI 10.1111/j.1574-695X.2005.00009.x.
44. Harris JK, De Groote MA, Sagel SD, Zemanick ET, Kapsner R, Penvari C, Kaess H, Deterding RR, Accurso FJ, Pace NR. 2007. Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis. Proceedings of the National Academy of Sciences of the United States of America 104(51):20529-20533 DOI 10.1073/pnas.0709804104.
45. Hirschhausen N, Block D, Bianconi I, Bragonzi A, Birtel J, Lee JC, Dübbers A, Küster P, Kahl J, Peters G, Kahl BC. 2013. Extended Staphylococcus aureus persistence in cystic fibrosis is associated with bacterial adaptation. International Journal of Medical Microbiology 303(8):685-692 DOI 10.1016/j.ijmm.2013.09.012.
46. Høiby N. 1982. Microbiology of lung infections in cystic fibrosis patients. Acta Pædiatrica 71:33-54 DOI 10.1111/j.1651-2227.1982.tb09640.x.
47. Høiby N, Frederiksen B, Pressler T. 2005. Eradication of early Pseudomonas aeruginosa infection. Journal of Cystic Fibrosis 4(Supplement 2):49-54 DOI 10.1016/j.jcf.2005.05.018.
48. Holden MTG, Feil EJ, Lindsay JA, Peacock SJ, Day NPJ, Enright MC, Foster TJ, Moore CE, Hurst L, Atkin R, Barron A, Bason N, Bentley SD, Chillingworth C, Chillingworth T, Churcher C, Clark L, Corton C, Cronin A, Doggett J, Dowd L, Feltwell T, Hance Z, Harris B, Hauser H, Holroyd S, Jagels K, James KD, Lennard N, Line A, Mayes R, Moule S, Mungall K, Ormond D, Quail MA, Rabbinowitsch E, Rutherford K, Sanders M, Sharp S, Simmonds M, Stevens K, Whitehead S, Barrell BG, Spratt BG, Parkhill J. 2004. Complete genomes of two clinical Staphylococcus aureus strains: evidence for the rapid evolution of virulence and drug resistance. Proceedings of the National Academy of Sciences of the United States of America 101(26):9786-9791 DOI 10.1073/pnas.0402521101.
49. Hu Y, Zhu Y, Ma Y, Liu F, Lu N, Yang X, Luan C, Yi Y, Zhu B. 2015. Genomic insights into intrinsic and acquired drug resistance mechanisms in Achromobacter xylosoxidans. Antimicrobial Agents and Chemotherapy 59(2):1152-1161 DOI 10.1128/AAC.04260-14.
50. Jakobsen TH, Hansen MA, Jensen PØ, Hansen L, Riber L, Cockburn A, Kolpen M, Rønne HC, Ridderberg W, Eickhardt S, Hansen M, Kerpedjiev P, Alhede M, Qvortrup K, Burmølle M, Moser C, Kühl M, Ciofu O, Givskov M, Sørensen SJ, Høiby N, Bjarnsholt T. 2013. Complete genome sequence of the cystic fibrosis pathogen Achromobacter xylosoxidans NH44784-1996 complies with important pathogenic phenotypes. PLoS ONE 8(7):e68484 DOI 10.1371/journal.pone.0068484.
51. Karakawa WW, Sutton A, Schneerson R, Karpas A, Vann WF. 1988. Capsular antibodies induce type-specific phagocytosis of capsulated Staphylococcus aureus by human polymorphonuclear leukocytes. Infection and Immunity 56(5):1090-1095.
52. Kaur R, Chang A, Xu Q, Casey JR, Pichichero ME. 2011. Phylogenetic relatedness and diversity of non-typable Haemophilus influenzae in the nasopharynx and middle ear fluid of children with acute otitis media. Journal of Medical Microbiology 60(12):1841-1848 DOI 10.1099/jmm.0.034041-0.
53. Koulenti D, Lisboa T, Brun-Buisson C, Krueger W, Macor A, Sole-Violan J, Diaz E, Topeli A, DeWaele J, Carneiro A, Martin-Loeches I, Armaganidis A, Rello J. 2009. Spectrum of practice in the diagnosis of nosocomial pneumonia in patients requiring mechanical ventilation in European intensive care units. Critical Care Medicine 37(8):2360-2368 DOI 10.1097/CCM.0b013e3181a037ac.
54. Krasan GP, Cutter D, Block SL, St. Geme JW. 1999. Adhesin expression in matched nasopharyngeal and middle ear isolates of nontypeable Haemophilus influenzae from children with acute otitis media. Infection and Immunity 67(1):449-454.
55. Li H, Durbin R. 2009. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25(14):1754-1760 DOI 10.1093/bioinformatics/btp324.
56. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, 1000 Genome Project Data Processing Subgroup. 2009. The sequence alignment/map format and SAMtools. Bioinformatics 25(16):2078-2079 DOI 10.1093/bioinformatics/btp352.
57. Lim YW, Evangelista 3rd JS, Schmieder R, Bailey B, Haynes M, Furlan M, Maughan H, Edwards R, Rohwer F, Conrad D. 2014. Clinical insights from metagenomic analysis of sputum samples from patients with cystic fibrosis. Journal of Clinical Microbiology 52(2):425-437 DOI 10.1128/JCM.02204-13.
58. Lopes SP, Ceri H, Azevedo NF, Pereira MO. 2012. Antibiotic resistance of mixed biofilms in cystic fibrosis: impact of emerging microorganisms on treatment of infection. International Journal of Antimicrobial Agents 40(3):260-263 DOI 10.1016/j.ijantimicag.2012.04.020.
59. Luo R, Liu B, Xie Y, Li Z, Huang W, Yuan J, He G, Chen Y, Pan Q, Liu Y, Tang J, Wu G, Zhang H, Shi Y, Liu Y, Yu C, Wang B, Lu Y, Han C, Cheung DW, Yiu S-M, Peng S, Xiaoqian Z, Liu G, Liao X, Li Y, Yang H, Wang J, Lam T-W, Wang J. 2012. SOAPdenovo2: an empirically improved memory-efficient short-read de novo assembler. GigaScience 1:18 DOI 10.1186/2047-217X-1-18.
60. Makarova KS, Haft DH, Barrangou R, Brouns SJJ, Charpentier E, Horvath P, Moineau S, Mojica FJM, Wolf YI, Yakunin AF, Van der Oost J, Koonin EV. 2011. Evolution and classification of the CRISPR-Cas systems. Nature Reviews Microbiology 9(6):467-477 DOI 10.1038/nrmicro2577.
61. McArthur AG, Waglechner N, Nizam F, Yan A, Azad MA, Baylay AJ, Bhullar K, Canova MJ, De Pascale G, Ejim L, Kalan L, King AM, Koteva K, Morar M, Mulvey MR, O'Brien JS, Pawlowski AC, Piddock LJV, Spanogiannopoulos P, Sutherland AD, Tang I, Taylor PL, Thaker M, Wang W, Yan M, Yu T, Wright GD. 2013. The comprehensive antibiotic resistance database. Antimicrobial Agents and Chemotherapy 57(7):3348-3357 DOI 10.1128/AAC.00419-13.
62. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, DePristo MA. 2010. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Research 20(9):1297-1303 DOI 10.1101/gr.107524.110.
63. Nakamura S, Shchepetov M, Dalia AB, Clark SE, Murphy TF, Sethi S, Gilsdorf JR, Smith AL, Weiser JN. 2011. Molecular basis of increased serum resistance among pulmonary isolates of non-typeable Haemophilus influenzae. PLoS Pathogens 7(1):e1001247 DOI 10.1371/journal.ppat.1001247.
64. Nimmo GR, Pearson JC, Collignon PJ, Christiansen KJ, Coombs GW, Bell JM, McLaws M-L, Resistance AGOA. 2011. Antimicrobial susceptibility of Staphylococcus aureus isolated from hospital inpatients, 2009: report from the Australian group on antimicrobial resistance. Communicable Diseases Intelligence 35(3):237-243.
65. Parks DH, Imelfort M, Skennerton CT, Hugenholtz P, Tyson GW. 2015. CheckM: assessing the quality of microbial genomes recovered from isolates, single cells, and metagenomes. Genome Research 25:1043-1055 DOI 10.1101/gr.186072.114.
66. Peacock SJ, Moore CE, Justice A, Kantzanou M, Story L, Mackie K, O'Neill G, Day NPJ. 2002. Virulent combinations of adhesin and toxin genes in natural populations of Staphylococcus aureus. Infection and Immunity 70(9):4987-4996 DOI 10.1128/IAI.70.9.4987-4996.2002.
67. Pöhlmann-Dietze P, Ulrich M, Kiser KB, Döring G, Lee JC, Fournier J-M, Botzenhart K, Wolz C. 2000. Adherence of Staphylococcus aureus to endothelial cells: influence of capsular polysaccharide, global regulatoragr, and bacterial growth phase. Infection and Immunity 68(9):4865-4871 DOI 10.1128/IAI.68.9.4865-4871.2000.
68. Pompilio A, Pomponio S, Crocetta V, Gherardi G, Verginelli F, Fiscarelli E, Dicuonzo G, Savini V, D'Antonio D, Di Bonaventura G. 2011. Phenotypic and genotypic characterization of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis: genome diversity, biofilm formation, and virulence. BMC Microbiology 11:159 DOI 10.1186/1471-2180-11-159.
69. Quinlan AR, Hall IM. 2010. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics 26(6):841-842 DOI 10.1093/bioinformatics/btq033.
70. Quon BS, Aitken ML. 2012. Cystic fibrosis: what to expect now in the early adult years. Paediatric Respiratory Reviews 13(4):206-214 DOI 10.1016/j.prrv.2012.03.005.
71. Rau MH, Hansen SK, Johansen HK, Thomsen LE, Workman CT, Nielsen KF, Jelsbak L, Høiby N, Yang L, Molin S. 2010. Early adaptive developments of Pseudomonas aeruginosa after the transition from life in the environment to persistent colonization in the airways of human cystic fibrosis hosts. Environmental Microbiology 12(6):1643-1658 DOI 10.1111/j.1462-2920.2010.02211.x.
72. Razvi S, Quittell L, Sewall A, Quinton H, Marshall B, Saiman L. 2009. Respiratory microbiology of patients with cystic fibrosis in the united states, 1995 to 2005. Chest 136(6):1554-1560 DOI 10.1378/chest.09-0132.
73. Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Jones G, Bruce KD. 2004. Characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16s ribosomal DNA terminal restriction fragment length polymorphism profiling. Journal of Clinical Microbiology 42(11):5176-5183 DOI 10.1128/JCM.42.11.5176-5183.2004.
74. Rolain JM, Fancello L, Desnues C, Raoult D. 2011. Bacteriophages as vehicles of the resistome in cystic fibrosis. Journal of Antimicrobial Chemotherapy 66(11):2444-2447 DOI 10.1093/jac/dkr318.
75. Rønne Hansen C, Pressler T, Høiby N, Gormsen M. 2006. Chronic infection with Achromobacter xylosoxidans in cystic fibrosis patients; a retrospective case control study. Journal of Cystic Fibrosis 5(4):245-251 DOI 10.1016/j.jcf.2006.04.002.
76. Sagel SD, Gibson RL, Emerson J, McNamara S, Burns JL, Wagener JS, Ramsey BW. 2009. Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. Journal of Pediatrics 154(2):183-188 DOI 10.1016/j.jpeds.2008.08.001.
77. Sibley CD, Rabin H, Surette MG. 2006. Cystic fibrosis: a polymicrobial infectious disease. Future Microbiology 1(1):53-61 DOI 10.2217/17460913.1.1.53.
78. Smith EE, Buckley DG, Wu ZN, Saenphimmachak C, Hoffman LR, D'Argenio DA, Miller SI, Ramsey BW, Speert DP, Moskowitz SM, Burns JL, Kaul R, Olson MV. 2006. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proceedings of the National Academy of Sciences of the United States of America 103(22):8487-8492 DOI 10.1073/pnas.0602138103.
79. St. Geme JW, Kumar VV, Cutter D, Barenkamp SJ. 1998. Prevalence and distribution of the hmw and hia genes and the HMW and Hia adhesins among genetically diverse strains of nontypeable Haemophilus influenzae. Infection and Immunity 66(1):364-368.
80. Steinkamp G, Wiedemann B, Rietschel E, Krahl A, Gielen J, Bärmeier H, Ratjen F. 2005. Prospective evaluation of emerging bacteria in cystic fibrosis. Journal of Cystic Fibrosis 4(1):41-48 DOI 10.1016/j.jcf.2004.10.002.
81. Svensson-Stadler LA, Mihaylova SA, Moore ERB. 2012. Stenotrophomonas interspecies differentiation and identification by gyrB sequence analysis. FEMS Microbiology Letters 327(1):15-24 DOI 10.1111/j.1574-6968.2011.02452.x.
82. Swain MT, Tsai IJ, Assefa SA, Newbold C, Berriman M, Otto TD. 2012. A post-assembly genome-improvement toolkit (PAGIT) to obtain annotated genomes from contigs. Nature Protocols 7(7):1260-1284 DOI 10.1038/nprot.2012.068.
83. Talmaciu I, Varlotta L, Mortensen J, Schidlow DV. 2000. Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis. Pediatric Pulmonology 30(1):10-15 DOI 10.1002/1099-0496(200007)30:1<10::AID-PPUL3>3.0.CO;2-Q.
84. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. 2013. MEGA6: molecular evolutionary genetics analysis version 6.0. Molecular Biology and Evolution 30(12):2725-2729 DOI 10.1093/molbev/mst197.
85. Tsai IJ, Otto TD, Berriman M. 2010. Improving draft assemblies by iterative mapping and assembly of short reads to eliminate gaps. Genome Biology 11(4):R41 DOI 10.1186/gb-2010-11-4-r41.
86. Tunney MM, Field TR, Moriarty TF, Patrick S, Doering G, Muhlebach MS, Wolfgang MC, Boucher R, Gilpin DF, McDowell A, Elborn JS. 2008. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 177(9):995-1001 DOI 10.1164/rccm.200708-1151OC.
87. Turton JF, Mustafa N, Shah J, Hampton CV, Pike R, Kenna DT. 2011. Identification of Achromobacter xylosoxidans by detection of the blaOXA-114-like gene intrinsic in this species. Diagnostic Microbiology and Infectious Disease 70(3):408-411 DOI 10.1016/j.diagmicrobio.2011.02.007.
88. Valdezate S, Vindel A, Maiz L, Baquero F, Escobar H, Canton R. 2001. Persistence and variability of Stenotrophomonas maltophilia in cystic fibrosis patients, Madrid, 1991-1998. Emerging Infectious Diseases 7(1):113-122 DOI 10.3201/eid0701.010116.
89. Van der Gast CJ, Walker AW, Stressmann FA, Rogers GB, Scott P, Daniels TW, Carroll MP, Parkhill J, Bruce KD. 2011. Partitioning core and satellite taxa from within cystic fibrosis lung bacterial communities. ISME Journal 5(5):780-791 DOI 10.1038/ismej.2010.175.
90. Von Eiff C, Becker K, Machka K, Stammer H, Peters G. 2001. Nasal carriage as a source of Staphylococcus aureus bacteremia. New England Journal of Medicine 344(1):11-16 DOI 10.1056/NEJM200101043440102.
91. Vu-Thien H, Hormigos K, Corbineau G, Fauroux B, Corvol H, Moissenet D, Vergnaud G, Pourcel C. 2010. Longitudinal survey of Staphylococcus aureus in cystic fibrosis patients using a multiple-locus variable-number of tandem-repeats analysis method. BMC Microbiology 10(1):24 DOI 10.1186/1471-2180-10-24.
92. Wang JM, Mullighan CG, Easton J, Roberts S, Heatley SL, Ma J, Rusch MC, Chen K, Harris CC, Ding L, Holmfeldt L, Payne-Turner D, Fan X, Wei L, Zhao D, Obenauer JC, Naeve C, Mardis ER, Wilson RK, Downing JR, Zhang JH. 2011. CREST maps somatic structural variation in cancer genomes with base-pair resolution. Nature Methods 8(8):652-654 DOI 10.1038/nmeth.1628.
93. Waters V, Yau Y, Prasad S, Lu A, Atenafu E, Crandall I, TomS, Tullis E, Ratjen F. 2011. Stenotrophomonas maltophilia in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 183(5):635-640 DOI 10.1164/rccm.201009-1392OC.
94. Wertheim HFL, Melles DC, Vos MC, Van Leeuwen W, Van Belkum A, Verbrugh HA, Nouwen JL. 2005. The role of nasal carriage in Staphylococcus aureus infections. The Lancet Infectious Diseases 5(12):751-762 DOI 10.1016/S1473-3099(05)70295-4.
95. Yang L, Jelsbak L, Marvig RL, Damkiaer S, Workman CT, Rau MH, Hansen SK, Folkesson A, Johansen HK, Ciofu O, Hoiby N, Sommer MOA, Molin S. 2011. Evolutionary dynamics of bacteria in a human host environment. Proceedings of the National Academy of Sciences of the United States of America 108(18):7481-7486 DOI 10.1073/pnas.1018249108.
96. Young DM, Ornston LN. 2001. Functions of the mismatch repair gene mutS from Acinetobacter sp. strain ADP1. Journal of Bacteriology 183(23):6822-6831 DOI 10.1128/JB.183.23.6822-6831.2001.
97. Zhao J, Schloss PD, Kalikin LM, Carmody LA, Foster BK, Petrosino JF, Cavalcoli JD, VanDevanter DR, Murray S, Li JZ, Young VB, LiPuma JJ. 2012. Decade-long bacterial community dynamics in cystic fibrosis airways. Proceedings of the National Academy of Sciences of the United States of America 109(15):5809-5814 DOI 10.1073/pnas.1120577109.
98. Zhou Y, Liang Y, Lynch KH, Dennis JJ, Wishart DS. 2011. PHAST: a fast phage search tool. Nucleic Acids Research 39:W347-W352 DOI 10.1093/nar/gkr485.